Chemomab Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Equivalents	9.37	13.6	15.19	11.67	17.58	7.52	1.45	4.56
Short-Term Investments	10.49	26.37	45.98	0.02	0	0	0	0
Cash & Cash Equivalents	19.86	39.97	61.16	11.7	17.58	7.52	1.45	4.56
Cash Growth	-50.31%	-34.65%	422.83%	-33.44%	133.80%	416.99%	-68.14%	-
Receivables	1.04	1.77	1.53	0.14	0	3.4	0.4	0.87
Other Current Assets	0	0	0	0	0.64	0	0	0
Total Current Assets	20.9	41.74	62.69	11.84	18.21	10.92	1.85	5.43
Property, Plant & Equipment	0.7	0.59	0.7	0.58	1.36	0.39	0.22	0.21
Long-Term Investments	0	0	0.06	0.06	0.13	0.12	0	0
Other Long-Term Assets	0.56	0.73	0.91	0	0.06	1.34	0.01	0.01
Total Long-Term Assets	1.25	1.33	1.67	0.64	1.54	1.84	0.23	0.22
Total Assets	22.15	43.06	64.35	12.48	19.76	12.76	2.09	5.66
Accounts Payable	0.52	1.69	1.34	0.09	0.88	2.1	2.54	2.22
Current Debt	0.08	0.12	0.11	0.07	0.39	0	0	0
Other Current Liabilities	4.25	4.94	1.21	1.15	2.86	0.64	0.16	0.14
Total Current Liabilities	4.84	6.75	2.65	1.32	4.12	2.75	2.7	2.36
Long-Term Debt	0.32	0.09	0.24	0.36	0.73	0	0	0
Other Long-Term Liabilities	0	0	0	0	0	0.21	0	0
Total Long-Term Liabilities	0.32	0.09	0.24	0.36	0.73	0.21	0	0
Total Liabilities	5.15	6.84	2.89	1.67	4.85	2.96	2.7	2.36
Total Debt	0.39	0.21	0.34	0.43	1.12	0	0	0
Debt Growth	83.18%	-37.61%	-19.86%	-61.65%	-	-	-	-
Retained Earnings	-88.68	-63.82	-36.17	-23.7	-105.43	-78.31	-62.88	-53.07
Comprehensive Income	0	0	0	0	0.87	0.87	0.46	0.2
Shareholders' Equity	17	36.22	61.47	10.8	14.91	9.81	-0.61	3.3
Net Cash / Debt	19.47	39.76	60.82	11.27	16.46	7.52	1.45	4.56
Net Cash / Debt Growth	-51.03%	-34.63%	439.65%	-31.53%	118.96%	416.99%	-68.14%	-
Net Cash Per Share	0.08	0.17	0.29	0.08	1.91	2.38	-	-
Working Capital	16.06	34.99	60.04	10.52	14.09	8.17	-0.84	3.07
Book Value Per Share	1.45	3.18	5.92	1.58	34.63	62.09	-1.48	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).